ReviewInternational urology and nephrology2019
Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics.
Review in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.International urology and nephrology · 2023Trial
- Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients.Cell death discovery · 2025Article
- Eosinophils but not mast cells exert anti-tumorigenic activity, without being predictive markers of the long-term response to Bacillus Calmette-Guérin (BCG) therapy in patients with bladder carcinoma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.International journal of cancer · 2025Article
- Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.Translational cancer research · 2024Review
- Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.Annals of surgical oncology · 2024Observational
- Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.International journal of molecular sciences · 2024Review
- Article
- Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy.Annals of surgical oncology · 2024Article
- Article
- Mean platelet volume to lymphocyte ratio as an inflammatory marker associated with high-grade recurrence and progression of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.Central European journal of urology · 2024Article
- Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.Annals of surgical oncology · 2023Article
- Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis.Annals of surgical oncology · 2023Article
- ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.Annals of surgical oncology · 2023Article
- Article
- Quitting smoking after a cancer diagnosis is associated with high-risk neutrophil-to-lymphocyte ratio among tobacco use-related cancer survivors.Scientific reports · 2023Article
- State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.Biosensors · 2022Review
- Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.Frontiers in oncology · 2022Review
- Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacillus Calmette-Guerin (BCG) instillations are considered as a gold standard of therapy in high- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Unfortunately, up to 40% of patients might experience treatment failure and even 15% of patients initially diagnosed with NMIBC will progress to muscle-invasive disease. Since patients, who fail to respond to BCG, are at particular risk of progression, immediate radical cystectomy (RC) is currently recommended to provide cancer control. However, immunotherapy in NMIBC management still evolves. Immune checkpoint inhibitors emerge as new immunotherapeutics, which in the future might be combined with BCG and may serve as an alternative to radical cystectomy in patients, who failed to respond to BCG alone or are at particular a priori risk of BCG failure, especially if RC is not a safe option. Therefore, there is an urgent need to identify NMIBC patients that will not benefit from BCG therapy and demand radical cystectomy. In the following review, we attempt to focus on several clinical and molecular factors and demonstrate the efforts directed to unravel their significance in BCG-failure risk assessment.
Indexed as
Identifiers
31154583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.